Minerva Neurosciences, Inc (NASDAQ:NERV) is reporting third quarter financial results on Monday 2nd November 2020, before market open.
According to analysts surveyed by Thomson Reuters, NERV is expected to report 3Q20 loss of $ 0.23 per share
For the full year, analysts anticipate top line of $ 41.19 million, while looking forward to loss of $ 0.01 per share bottom line.
Stock Performance
On Friday, shares of Minerva Neurosciences, Inc has traded high as $ 3.22 and has cracked $ 3.12 on the downward trend, reaching $ 3.21 with volume of 485.30 thousand shares.
According to the previous trading day, closing price of $ 3.21, representing a 79.01 % increase from the 52 week low of $ 1.81 and a 78.71 % decrease over the 52 week high of $ 15.22.
The company has a market capital of $ 132.27 million and is part of the Healthcare sector and Biotechnology industry.
Conference Call
Minerva Neurosciences, Inc will be hosting a conference call at 8:30 AM eastern time on 2nd November 2020, to discuss its 3Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.minervaneurosciences.com
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of a portfolio of product candidates for the treatment of central nervous system diseases. The companys lead product candidate is roluperidone, which is in Phase III clinical trial, a compound for the treatment of patients with schizophrenia. It also offers MIN-117, a compound that has completed Phase IIb clinical trial for the treatment of patients suffering from major depressive disorder (MDD); and seltorexant, which is in Phase IIb clinical trial for treating insomnia and MDD.
